Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells

被引:22
|
作者
Koethe, Susanne [1 ]
Mueller, Joerg P. [1 ]
Boehmer, Sylvia-Annette [1 ]
Tschongov, Todor [1 ]
Fricke, Melanie [1 ]
Koch, Sina [2 ,3 ]
Thiede, Christian [2 ]
Requardt, Robert P. [4 ]
Rubio, Ignacio [1 ,4 ]
Boehmer, Frank D. [1 ]
机构
[1] Jena Univ Hosp, Ctr Mol Biomed, Inst Mol Cell Biol, D-07743 Jena, Germany
[2] Univ Hosp Carl Gustav Carus, Mol Hematol Grp, Dept Internal Med 1, D-01307 Dresden, Germany
[3] Max Planck Inst Mol Physiol, Dept Syst Cell Biol, D-44227 Dortmund, Germany
[4] Jena Univ Hosp, CSCC, D-07743 Jena, Germany
关键词
Oncogenic RTK; FLT3; ITD; Leukemia; AML; Ras; Localization; Plasma membrane; Endomembrane; ENDOPLASMIC-RETICULUM; MUTATIONS; GENE; TRANSFORMATION; MUTANTS; GROWTH; IMPAIRS; PANEL; KIT;
D O I
10.1242/jcs.131789
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
FMS-like tyrosine kinase 3 with internal tandem duplication (FLT3 ITD) is an important oncoprotein in acute myeloid leukemia (AML). Owing to its constitutive kinase activity FLT3 ITD partially accumulates at endomembranes, a feature shared with other disease-associated, mutated receptor tyrosine kinases. Because Ras proteins also transit through endomembranes we have investigated the possible existence of an intracellular FLT3-ITD/Ras signaling pathway by comparing Ras signaling of FLT3 ITD with that of wild-type FLT3. Ligand stimulation activated both K- and N-Ras in cells expressing wild-type FLT3. Live-cell Ras-GTP imaging revealed ligand-induced Ras activation at the plasma membrane (PM). FLT3-ITD-dependent constitutive activation of K-Ras and N-Ras was also observed primarily at the PM, supporting the view that the PM-resident pool of FLT3 ITD engaged the Ras/Erk pathway in AML cells. Accordingly, specific interference with FLT3-ITD/Ras signaling at the PM using PM-restricted dominant negative K-RasS17N potently inhibited cell proliferation and promoted apoptosis. In conclusion, Ras signaling is crucial for FLT3-ITD-dependent cell transformation and FLT3 ITD addresses PM-bound Ras despite its pronounced mislocalization to endomembranes.
引用
收藏
页码:4746 / 4755
页数:10
相关论文
共 50 条
  • [21] Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice
    Cutts, Briony A.
    Sjogren, Anna-Karin M.
    Andersson, Karin M. E.
    Wahlstrom, Annika M.
    Karlsson, Christin
    Swolin, Birgitta
    Bergo, Martin O.
    BLOOD, 2009, 114 (17) : 3629 - 3632
  • [22] FREQUENCY OF K-RAS MUTATION AND ITS CLINICAL FEATURES IN KOREAN ADULT ACUTE MYELOID LEUKEMIA
    Park, Mi-Jung
    Park, Soon-Ho
    Ahn, Jeong-Yeal
    Park, Pil-Whan
    Seo, Yiel-Hea
    Kim, Kyung-Hee
    Jeong, Ji-Hun
    Lee, Jae-Hoon
    Hong, Jun-Shik
    Kim, Hye-Ryoun
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2012, 34 : 71 - 71
  • [23] Core binding factor acute myeloid leukemia: Advances in the heterogeneity of KIT, FLT3, and RAS mutations
    Quan, Xi
    Deng, Jianchuan
    MOLECULAR AND CLINICAL ONCOLOGY, 2020, 13 (02) : 95 - 100
  • [24] Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
    McMahon, Christine M.
    Ferng, Timothy
    Canaani, Jonathan
    Wang, Eunice S.
    Issette, Jennifer J. D. Morr
    Eastburn, Dennis J.
    Pellegrino, Maurizio
    Durruthy-Durruthy, Robert
    Watt, Christopher D.
    Asthana, Saurabh
    Lasater, Elisabeth A.
    DeFilippis, RosaAnna
    Peretz, Cheryl A. C.
    McGary, Lisa H. F.
    Deihimi, Safoora
    Logan, Aaron C.
    Luger, Selina M.
    Shah, No P.
    Carroll, Martin
    Smith, Catherine C.
    Perl, Alexander E.
    CANCER DISCOVERY, 2019, 9 (08) : 1050 - 1063
  • [25] Shikonin exerts an anti-leukemia effect against FLT3-ITD mutated acute myeloid leukemia cells via targeting FLT3 tyrosine kinase and its downstream pathways
    Zhao, Mu-Nan
    Su, Long
    Song, Fei
    Wei, Zhi-Feng
    Qin, Tian-Xue
    Zhang, Yun-Wei
    Li, Wei
    Gao, Su-Jun
    ACTA HAEMATOLOGICA, 2023, : 310 - 323
  • [26] Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia
    Baker, Sharyn D.
    Zimmerman, Eric I.
    Wang, Yong-Dong
    Orwick, Shelley
    Zatechka, Douglas S.
    Buaboonnam, Jassada
    Neale, Geoffrey A.
    Olsen, Scott R.
    Enemark, Eric J.
    Shurtleff, Sheila
    Rubnitz, Jeffrey E.
    Mullighan, Charles G.
    Inaba, Hiroto
    CLINICAL CANCER RESEARCH, 2013, 19 (20) : 5758 - 5768
  • [27] FLT3 TYROSINE KINASE DOMAIN (TKD) MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
    Markova, J.
    Michkova, P.
    Maaloufova, J.
    Cetkovsky, P.
    Schwarz, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 550 - 550
  • [28] FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia
    Grunwald, Michael R.
    Levis, Mark J.
    SEMINARS IN HEMATOLOGY, 2015, 52 (03) : 193 - 199
  • [29] CABOZANTINIB IS SELECTIVELY CYTOTOXIC IN ACUTE MYELOID LEUKEMIA CELLS WITH INTERNAL TANDEM DUPLICATION OF FLT3 (FLT3-ITD)
    Wang, A.
    Lu, J. W.
    Hou, H. A.
    Chen, C. Y.
    Hu, C. Y.
    Ou, D. L.
    Ko, Y. C.
    Tien, H. F.
    Lin, L. I.
    HAEMATOLOGICA, 2014, 99 : 291 - 291
  • [30] KI2011 is a novel potent FLT3 tyrosine kinase inhibitor in acute myeloid leukemia cells with FLT3-mutation
    Ryu, Hwani
    Song, Jie-Young
    Ahn, Jiyeon
    CANCER RESEARCH, 2018, 78 (13)